Erkang Pharmaceutical released its 2026 interim report, with total operating revenue of 568 million yuan, down 16.77% year-on-year, and net profit attributable to the parent of 44.469 million yuan. Net cash flow from operating activities was negative 154 million yuan, a decline of 436.04% compared with the same period last year. The company's latest asset-liability ratio was 20.62%, gross margin was 31.36%, return on equity was 1.11%, and diluted earnings per share was 0.02 yuan. The number of shareholders was 43,200, and the top ten shareholders held 52.31% of the total share capital.
Hunan Er Kang PharmaceuticalNet profit down 16.77% YoY, operating cash flow negative 154 million yuan, decline of 436.04%